Heterogeneity of the long-term economic burden of severe sickle cell disease: a 5-year longitudinal analysis
CONCLUSION: Results indicate high clinical need and economic burden among patients with severe presentation of SCD. These findings not only highlight the need for improved therapeutic options to limit or prevent disease progression, but also starts to provide insight on lifetime costs of SCD that will be needed in the evaluation of emerging curative intent therapies.PMID:36222016 | DOI:10.1080/13696998.2022.2133824
Source: Journal of Medical Economics - Category: Health Management Authors: Meghan Gallagher Anjulika Chawla Brenna L Brady Sherif M Badawy Source Type: research
More News: Databases & Libraries | Economics | Emergency Medicine | Gene Therapy | Genetics | Health Management | Healthcare Costs | Insurance | Medicaid | Medicare | Sickle Cell Anemia | Stroke | Study